Navigation Links
Trovagene Expands NPM Patent Coverage
Date:9/25/2013

SAN DIEGO, Sept. 25, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced the issuance of U.S. Patent 8,501,924, "Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof." The patent pertains to nucleic acid sequences encoding NPM mutants and methods of detecting them for diagnosing acute myeloid leukemia (AML) and monitoring residual AML disease. This is the second issued U.S. patent directed to NPM mutants, and is part of a NPM-associated family of patents and applications for Trovagene. Previously, Trovagene announced issuance of U.S. Patent 8,222,370, the first patent to issue in the U.S. Additional claims directed to detecting NPM mutations are pending in the U.S. and abroad.      

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

"While the NPM patent family is an asset that has value as an incremental revenue stream, Trovagene continues to develop its cell-free molecular diagnostic tests for cancer monitoring," states Antonius Schuh, Ph.D., chief executive officer of Trovagene.  "Currently, Trovagene has licensing programs with multiple organizations including Labcorp, Quest Labs, Genoptix, Duke University and others. We intend to continue to develop additional licensing relationships that can add supplemental value."

The National Comprehensive Cancer Network (www.nccn.org), which sets clinical standards for cancer treatment, has included testing for NPM mutations in their clinical practice guidelines. Mutation analysis of nucleophosmin-1 (NPM1) helps physicians to select more appropriate treatment strategies for AML patients. NPM1 testing may also be useful for monitoring the effectiveness of treatment, minimal residual disease monitoring and detecting relapse, and stratifying AML patients when enrolling in clinical trials.

About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2012 and other periodic reports filed with the Securities and Exchange Commission.

Contact:
Trovagene, Inc.                                                          
Stephen Zaniboni
Chief Financial Officer
Trovagene, Inc.
858-952-7594
szaniboni@trovagene.com


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
2. Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine
3. Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
4. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
5. Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
6. Trovagene and Strand Life Sciences Agree to Validate and Commercialize Urine-Based HPV Test in India and South Asia
7. Trovagene, Inc., Announces Third Quarter and Year to Date Earnings, Provides Milestone Update
8. Dr. Paul Billings joins Trovagenes Scientific Advisory Board
9. Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
10. Trovagene and Barretos Cancer Hospital, Brazil, to Evaluate Urine-Based HPV Assay as Potential Pap Smear Replacement
11. Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... NEW YORK , Dec. 6, 2016 ... atomic nucleus. Radioisotopes are produced either by using nuclear ... energy in the form of alpha, beta or gamma ... thus emitted are used in Nuclear medicine, specifically in ... to provide diagnostic information about a human body,s functioning. ...
(Date:12/6/2016)... 6, 2016 Human Vaccines Market: Scope ... wise and country wise analysis of the human ... of human vaccines products, raw material suppliers, vaccine ... the market. The report provides qualitative and ... Qualitative analysis comprises market dynamics, trends, product overview, ...
(Date:12/6/2016)... BOLTON, Miss. , Dec. 6, 2016 ... and rescue personnel in a simulated mass casualty event ... Mississippi . The technology debuted before an audience ... Bryant and representatives from Homeland Security, Federal Law ... Telemedical Drone Project, known as HiRO (Health Integrated Rescue ...
Breaking Medicine Technology:
(Date:12/7/2016)... , ... December 07, 2016 , ... “Tomorrow Trump Goes ... Trump bringing greatness back to the presidency and to America. “Tomorrow Trump Goes To ... do as much as she can for this country. , Nancy attributes her patriotic ...
(Date:12/7/2016)... WI (PRWEB) , ... December 07, 2016 , ... ... Labs, was honored to present at the International Probiotic Association’s Washington DC workshop ... and government regulators to engage in dialog regarding probiotic dietary supplement regulations. ...
(Date:12/6/2016)... ... December 06, 2016 , ... Men ... a higher risk of serious health problems, such as cardiovascular illness, according to ... Soleymani of Beverly Hills Periodontics & Dental Implant Center notes that the correlation ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... health management, announces today a strategic relationship with CitiusTech, a leading healthcare ... engine that offers advanced Clinical Quality Measures (CQM) computation capabilities (as a ...
(Date:12/6/2016)... ... December 06, 2016 , ... CarriersEdge, providers of online ... new suite of Driver Wellness courses. Offered in three modules, the courses can be ... so fleets can educate drivers about how to stay healthy on the road. , ...
Breaking Medicine News(10 mins):